Although the development and clinical application of SARS-CoV-2 vaccines during the
COVID-19 pandemic demonstrated unprecedented vaccine success in a short time frame, it …

Nipah virus (NiV) causes severe encephalitis in humans. Three NiV strains NiV‐Malaysia
(NiVM), NiV Bangladesh (NiVB), and NiV India (NiVI reported in 2019) have been circulating …

Effective pandemic preparedness relies on anticipating viral mutations that are able to
evade host immune responses to facilitate vaccine and therapeutic design. However, current …

No licensed vaccines or therapies exist for patients infected with Nipah virus (NiV), although
an experimental human monoclonal antibody (mAb) cross-reactive to the NiV and Hendra …

Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic zoonotic henipaviruses
(HNVs) responsible for recurrent outbreaks of encephalitis and respiratory illness. As the …

Highlights•Summary of the basic principles of structure-based vaccine design.•Review of
recent advances (the years 2019–2021) in structure-based vaccine design.•Preview of …

Nipah virus causes highly lethal disease, with case-fatality rates ranging from 40% to 100%
in recognised outbreaks. No treatments or licensed vaccines are currently available for the …

In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from
patients with severe pneumonic disease in China. This virus is closely related to Mòjiāng …

Measles virus (MeV) presents a public health threat that is escalating as vaccine coverage in
the general population declines and as populations of immunocompromised individuals …

Nipah virus (NiV) represents a significant pandemic threat with zoonotic transmission from
bats-to-humans with almost annual regional outbreaks characterized by documented human …